文献速递肿瘤 PET/CT核素与放射性配体治疗

晚期转移性去势抵抗性前列腺癌患者肿瘤异质性检测:[68Ga]Ga-/[18F]F-PSMA-11/-1007、[68Ga]Ga-FAPI-46与2-[18F]FDG PET/CT先导研究

Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-08-29

本先导研究纳入10例晚期进展性转移性去势抵抗性前列腺癌(mCRPC)患者,行[68Ga]Ga-/[18F]F-PSMA-11/-1007、2-[18F]FDG及[68Ga]Ga-FAPI-46 PET/CT评估肿瘤异质性。共检测472个病灶,[68Ga]Ga-/[18F]F-PSMA-11/-1007检出率最高(96.0%)、半定量摄取最高。回顾性分为PSMA优势型7例与混合型3例,接受[177Lu]Lu-PSMA-617放射性配体治疗且归为PSMA优势型者中位总生存期较长(19.7 vs 9.3个月)。

要点

  • 10例mCRPC患者共检出472个病灶,[68Ga]Ga-/[18F]F-PSMA-11/-1007检出453个(96.0%)。
  • [68Ga]Ga-FAPI-46检出268个(56.8%),2-[18F]FDG检出241个(51.1%),两者相当。
  • 接受[177Lu]Lu-PSMA-617治疗且归为PSMA优势型者中位总生存期19.7 vs 9.3个月。

核心结论

  • 全身影像可识别mCRPC患者间及患者内 considerable 异质性及潜在影像表型。
  • 就摄取与肿瘤检出而言,[68Ga]Ga-/[18F]F-PSMA-11/-1007优于[68Ga]Ga-FAPI-46和2-[18F]FDG,后两者相当。
  • 接受[177Lu]Lu-PSMA-617放射性配体治疗且回顾性归为PSMA优势型者总生存期较长。

研究设计与样本

  • 先导研究,纳入10例晚期进展性mCRPC患者。
  • 患者行临床[68Ga]Ga-/[18F]F-PSMA-11/-1007、2-[18F]FDG及[68Ga]Ga-FAPI-46 PET/CT以评估PSMA导向放射性配体治疗。
  • 按病灶/区域比较肿瘤检出及半定量参数,并定义PSMA优势型与混合型两种表型。

主要发现

  • 共检出472个病灶,miTNM区域分布:M1b 327个(69.3%)、M1a 95个(20.1%)、N1 26个(5.5%)、M1c 18个(3.8%)、T 5个(1.1%)、Tr 1个(0.2%)。
  • [68Ga]Ga-/[18F]F-PSMA-11/-1007检出453个(96.0%),[68Ga]Ga-FAPI-46检出268个(56.8%),2-[18F]FDG检出241个(51.1%)。
  • 半定量摄取均值SUVmax(四分位距):[68Ga]Ga-/[18F]F-PSMA-11/-1007为22.7(22.5),[68Ga]Ga-FAPI-46为7.7(3.7),2-[18F]FDG为6.8(4.7)。
  • 7例回顾性归为PSMA优势型,3例归为混合型。
  • 接受[177Lu]Lu-PSMA-617放射性配体治疗且回顾性归为PSMA优势型者中位总生存期19.7 vs 9.3个月。

关键数值与推荐

  • 混合型表型标准:(a)淋巴结转移≥2.5 cm、任何实体器官转移≥1.0 cm或伴软组织成分≥1.0 cm的骨转移呈PSMA阴性;(b)[68Ga]Ga-/[18F]F-PSMA-11/-1007摄取低和/或(c)所有放射性配体肿瘤摄取均衡。
  • 未满足上述标准者归为PSMA优势型表型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In metastatic castration-resistant prostate cancer (mCRPC), some patients show low/absent PSMA expression in tumour lesions on positron emission tomography (PET) scans, indicating heterogeneity and heightened risk of non-response to PSMA-RLT (radioligand therapy). Imaging cancer-associated fibroblasts and glucose uptake may further characterise tumour heterogeneity in mCRPC patients. Here, we aimed to evaluate tumour heterogeneity and its potential implications for management in mCRPC patients assessed for PSMA-RLT using [68Ga]Ga-FAPI-46, 2-[18F]FDG and [68Ga]Ga-/[18F]F-PSMA-11/-1007 PET. MATERIAL AND METHODS: Patients with advanced, progressive mCRPC underwent clinical [68Ga]Ga-/[18F]F-PSMA-11/-1007, 2-[18F]FDG and [68Ga]Ga-FAPI-46 PET/CT to evaluate treatment with PSMA-directed RLT. Tumour detection/semiquantitative parameters were compared on a per-lesion/-region basis. Two phenotypes were defined: Criteria for the mixed phenotype were: (a) PSMA-negative findings for lymph node metastases ≥ 2.5 cm, any solid organ metastases ≥ 1.0 cm, or bone metastases with soft tissue component ≥ 1.0 cm, (b) low [68Ga]Ga-/[18F]F-PSMA-11/-1007 uptake and/or (c) balanced tumour uptake of all radioligands. The PSMA-dominant phenotype was assigned if the criteria were not met. RESULTS: In ten patients, 472 lesions were detected on all imaging modalities (miTNM regions: M1b: 327 (69.3%), M1a: 95 (20.1%), N1: 26 (5.5%), M1c: 18 (3.8%), T: 5 (1.1%) and Tr: 1 (0.2%). [68Ga]Ga-/[18F]F-PSMA-11/-1007 (n = 453 (96.0%)) demonstrates the highest detection rate, followed by [68Ga]Ga-FAPI-46 (n = 268 (56.8%))/2-[18F]FDG (n = 241 (51.1%)). Semiquantitative uptake was highest for [68Ga]Ga-/[18F]F-PSMA-11/-1007 (mean SUVmax (interquartile range): 22.7 (22.5), vs. [68Ga]Ga-FAPI-46 (7.7 (3.7)) and 2-[18F]FDG (6.8 (4.7)). Seven/three patients were retrospectively assigned to the PSMA-dominant/mixed phenotype. Median overall survival was significantly longer for patients who underwent [177Lu]Lu-PSMA-617 RLT and were retrospectively assigned to the PSMA-dominant phenotype (19.7 vs. 9.3 months). CONCLUSION: Through whole-body imaging, we identify considerable inter- and intra-patient heterogeneity of mCRPC and potential imaging phenotypes. Regarding uptake and tumour detection, [68Ga]Ga-/[18F]F-PSMA-11/-1007 was superior to [68Ga]Ga-FAPI-46 and 2-[18F]FDG, while the latter two were comparable. Patients who underwent [177Lu]Lu-PSMA-617 RLT based on clinical-decision making had a longer overall survival and could be assigned to the PSMA-dominant phenotype.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pabst KM, Mei R, Lückerath K, et al. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39207485. doi:10.1007/s00259-024-06891-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。